VISTA Eye Specialists works with Tzu Chi Malaysia to Help Restore Eyesight with 100 Charity Cataract Surgery
PETALING JAYA, Malaysia, Feb. 21, 2022 /PRNewswire/ -- In conjunction with World Sight Day 2021, VISTA Eye Specialist (VISTA) is continuing to support the fight towards eliminating preventable blindness by pledging to provide 100 Charity Cataract surgeries via a joint community service project with Tzu Chi Malaysia in improving the quality of life of the affected individuals and their...
Meihua International Medical Technologies Co., Ltd. Announces Closing of $39.4 Million Initial Public Offering
YANGZHOU, China, Feb. 19, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, today announced the closing of its initial public offering (the "Offering") of 3,940,000 ordinary shares at a public offering price...
OliPass Announces Commencement of Dosing in Phase 2a Trial for Pain Killer OLP-1002
SEOUL, South Korea, Feb. 18, 2022 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced that the dosing of pain killer OLP-1002 commenced for a Phase 2a trial in osteoarthritis patients with pain. The Phase 2a study was approved by the Australian regulatory agency in October last year. The Phase 2a...
Keymed Bio Joins Hang Seng Family of Indexes
HONG KONG, Feb. 18, 2022 /PRNewswire/ -- According to the quarterly review results of Hang Seng Family of Indexes, Keymed Biosciences Inc. (2162. HK) was included a constituent stock of: Hang Seng Composite Index; Hang Seng Small Cap (Investable) Index; Hang Seng Stock Connect Hong Kong Index; Hang Seng Stock Connect Hong Kong MidCap &...
The Johns Hopkins University’s Institute for Global Tobacco Control updates its free online course on the dangers of tobacco use and COVID-19
BALTIMORE, Feb. 18, 2022 /PRNewswire/ -- With the COVID-19 pandemic still a concern as 2022 begins, arm yourself with knowledge about the connection between tobacco use and COVID-19 with a free online course from the Institute for Global Tobacco Control at the Johns Hopkins Bloomberg School of Public Health. Arm yourself with knowledge about the connection between...
TransThera Announces that the IND Application of TT-01488, a Non-covalent Reversible BTK Inhibitor, for the Treatment of B-Cell Lymphomas has been Approved by the FDA in the US and...
NANJING, China, Feb. 18, 2022 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. ("TransThera") announced that the U.S. Food and Drug Administration ("FDA") approved the Investigational New Drug ("IND") application of TT-01488, a non-covalent reversible Bruton's Tyrosine Kinase ("BTK") inhibitor, for the treatment of B-cell lymphomas on January 24, 2022, and TransThera will initiate the Phase I clinical trials in the U.S....
HealthMetrics Helps Singapore Companies Streamline Corporate Healthcare Management
HealthMetrics platform is now available in Singapore to help companies save cost on corporate healthcare management. HealthMetrics has over 1,000 corporate clients including PwC, Surbana Jurong, and Decathlon as well as 200,000 corporate members in the region. SINGAPORE, Feb. 17, 2022 /PRNewswire/ -- HealthMetrics, a leading cloud enterprise healthcare management company has announced that its platform is now available in...
PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology
- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically - Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that the Phase IIa...
Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin’s Lymphoma
SUZHOU, China and PALO ALTO, Calif., Feb. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it has dosed multiple patients in a clinical trial evaluating...
Flat Medical joins the Stay Connected(R), the International Organization for Safer Neuraxial Anesthesia
TAIPEI, Feb. 17, 2022 /PRNewswire/ -- Flat Medical Co., Ltd., a MedTech company specializing in safety solutions for anesthesia and critical care procedures, has announced that it has just joined the Stay Connected®, a joint communication initiative on behalf of the industry to advocate and educate for the adoption of the NRFit® connector, a new and safer connector for...
